Allogeneic bone marrow transplantation in 24 patients with multiple myeloma reported to the EBMT registry.
Twenty-four patients with multiple myeloma received an allogeneic bone-marrow graft from HLA-compatible sibling donors (n = 23), or a twin donor (n = 1). Eighteen patients are alive, 1-36 months post bone-marrow transplantation (median 14 months). Ten of these patients had no signs of multiple myeloma as judged by immunoglobulins in serum, light chains in urine, or the percentage of plasma-cells in bone-marrow aspirate. Bone lesions on X-ray were mainly unchanged. Six patients died from transplant-related complications 3 weeks to 5 months post transplantation. One of these patients had severe acute graft-versus-host disease (aGVHD). In other patients aGVHD was a minor problem. Allogeneic bone-marrow transplantation appears to be a promising method for treatment of a selected group of patients with multiple myeloma.
Gahrton
G
G
Department of Medicine, Huddinge Hospital, Sweden.
Tura
S
S
Flesch
M
M
Gratwohl
A
A
Gravett
P
P
Lindeberg
A
A
Lucarelli
G
G
Michallet
M
M
Reiffers
J
J
Ringdén
O
O
D016026:Bone Marrow Transplantation; D005500:Follow-Up Studies; D006086:Graft vs Host Disease; D006801:Humans; D009101:Multiple Myeloma / Q000628:therapy*; D012042:Registries; D013548:Sweden; D014184:Transplantation, Homologous